(Alliance News) - Circassia Pharmaceuticals PLC said Monday it has appointed Jonathan Emms to the company's newly created role of chief operating officer.
In his new role at the respiratory disease-focused pharmaceutical firm, Emms will be responsible for leading the Circassia's commercial strategy and operational management.
Emms will be joining from Pfizer Inc where he spent 13 years since 2006, leaving as chief commercial officer for the US pharmaceutical firm's Internal Medicines unit.
Emms will join the Circassia board as executive director, replacing Senior Vice President for Research & Development Rob Hafner, who will step down as a director after 12 years since 2007.
Hafner will remain with the company and continue in his current role supporting Circassia's commercial operations.
"I would like to warmly welcome Jonathan to Circassia and to the board, and we look forward to benefiting from his extensive commercial expertise gained in the US, Europe and globally. As Circassia completes its transition into a commercially-focused organisation, Jonathan will play a key role driving both our commercial and operational capabilities," said Chair Francesco Granata.
Shares in Circassia Pharmaceuticals were down 1.3% at 18.90 pence on Monday.
